TY - JOUR T1 - Risk Factors for Pericardial Effusion in Patients with Stage I Esophageal Cancer Treated with Chemoradiotherapy JF - Anticancer Research JO - Anticancer Res SP - 7389 LP - 7393 VL - 34 IS - 12 AU - KEISUKE TAMARI AU - FUMIAKI ISOHASHI AU - YUICHI AKINO AU - OSAMU SUZUKI AU - YUJI SEO AU - YASUO YOSHIOKA AU - YOSHITO HAYASHI AU - TSUTOMU NISHIDA AU - TETSUO TAKEHARA AU - MASAKI MORI AU - YUICHIRO DOKI AU - KAZUHIKO OGAWA Y1 - 2014/12/01 UR - http://ar.iiarjournals.org/content/34/12/7389.abstract N2 - Aim: We investigated clinical and dosimetric factors influencing the risk of developing pericardial effusion (PCE) in patients with Stage I esophageal cancer undergoing definitive chemoradiotherapy. Patients and Methods: Sixty-nine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed. Results: The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 ≥41.6%, age ≥66 years, body mass index (BMI) ≥19 and diabetes mellitus (DM) were significant predictors of developing PCE. Conclusion: The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE. ER -